臨床泌尿器科68巻13号

2014年12月発行

特集 新時代を迎えたPET診断

腎癌に対するPETの有用性と今後の展望

著者： 加藤廉平¹ 伊藤明人¹ 加藤陽一郎¹ 岩崎一洋¹ 高田亮¹ 小原航¹

所属機関： ¹岩手医科大学医学部泌尿器科学教室

ページ範囲：P.1004 - P.1009

文献概要

要旨　従来の形態的画像評価に対し，機能的画像評価としてPETの有用性が報告され，臨床現場ではCTと組み合わせたPET/CTが広く行われるようになっている。腎癌ではFDG-PETで用いられる¹⁸F-FDGが尿中排泄であり尿路に生理的集積がみられるため，原発巣の同定には有用ではないとされてきたが，一連の検査で全身の画像検査が可能であり，PETとCTを組み合わせることでより高い感度が得られ，遠隔転移の診断に加えて再発の診断にも有用性が期待できる。また，進行性腎癌の治療は分子標的薬が中心となったが，治療効果判定のバイオマーカーが確立されていない現在，画像による治療効果判定としてPETが注目されている。

参考文献

1）日本泌尿器科学会（編）：腎癌診療ガイドライン2011年版（第2版）．金原出版，東京，2011

2）Lodde M, Lacombe L, Friede J, et al：Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 106：658-663, 2010

3）Sun SS, Chang CH, Ding HJ, et al：Preliminary study of detecting urothelial malignancy with FDG PET in Taiwanese ESRD patients. Anticancer Res 29：3459-3463, 2009

4）Majhail NS, Urbain JL, Albani JM, et al：F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21：3995-4000, 2003

5）Kang DE, White RL, Zuger JH, et al：Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171：1806-1809, 2004

6）Wu HC, Yen RF, Shen YY, et al：Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas：a preliminary report. J Cancer Res Clin Oncol 128：503-506, 2002

7）Grant FD, Fahey FH, Packard AB, et al：Skeletal PET with F-18-fluoride：applying new technology to an old tracer. J Nucl Med 49：68-78, 2008

8）Park JW, Jo MK, Lee HM：Significance of F-18-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 103：615-619, 2009

9）Nakatani K, Nakamoto Y, Saga T, et al：The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol 79：29-35, 2011

10）Eisenhauer EA, Therasse P, Bogaerts J, et al：New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）. Eur J Cancer 45：228-247, 2009

11）Motzer RJ, Hutson TE, Tomczak P, et al：Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356：115-124, 2007

12）Rini BI, Escudier B, Tomczak P, et al：Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma（AXIS）：a randomised phase 3 trial. Lancet 378：1931-1939, 2011

13）Iwasaki K, Obara W, Fujioka T：Case of complete response to everolimus for metastatic renal cell carcinoma. Int J Urol 19：891-892, 2012

14）Choi H, Charnsangavej C, Faria SC, et al：Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate：proposal of new computed tomography response criteria. J Clin Oncol 25：1753-1759, 2007

15）Choi H：Response evaluation of gastrointestinal stromal tumors. Oncologist 13（suppl 2）：4-7, 2008

16）van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, et al：Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102：803-809, 2010

17）Revheim ME, Winge-Main AK, Hagen G, et al：Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol（R Coll Radiol） 23：339-343, 2011

18）Kayani I, Avril N, Bomanji J, et al：Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17：6021-6028, 2011

19）Ueno D, Yao M, Tateishi U, et al：Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. Bmc Cancer 12：162, 2012

20）Chatal JF, Saccavini JC, Fumoleau P, et al：Immunoscintigraphy of colon carcinoma. J Nucl Med 25：307-314, 1984

21）Kahn D, Williams RD, Manyak MJ, et al：（111）Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 159：2041-2046, 1998

22）Halpern SE, Haindl W, Beauregard J, et al：Scintigraphy with In-111-labeled monoclonal antitumor antibodies：kinetics, biodistribution, and tumor detection. Radiology 168：529-36, 1988

23）Ivanov S, Liao SY, Ivanova A, et al：Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158：905-919, 2001

24）Oosterwijk E：Carbonic anhydrase Ⅸ：historical and future perspectives. BJU Int 101（suppl 4）：2-7, 2008

25）Divgi CR, Pandit-Taskar N, Jungbluth AA, et al：Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250（124I-cG250）and PET in patients with renal masses：a phase Ⅰ trial. Lancet Oncol 8：304-310, 2007

26）Choueiri TK, Regan MM, Rosenberg JE, et al：Carbonic anhydrase Ⅸ and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 106：772-778, 2010

27）Bui MH, Seligson D, Han KR, et al：Carbonic anhydrase Ⅸ is an independent predictor of survival in advanced renal clear cell carcinoma：implications for prognosis and therapy. Clin Cancer Res 9：802-811, 2003

28）Shields AF, Grierson JR, Dohmen BM, et al：Imaging proliferation in vivo with F-18 FLT and positron emission tomography. Nat Med 4：1334-1336, 1998

29）Liu G, Jeraj R, Vanderhoek M, et al：Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 17：7634-7644, 2011

In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med 51：1707-1715, 2010